Blueprint Medicines Corp (BPMC):企業の財務・戦略的SWOT分析

◆英語タイトル:Blueprint Medicines Corp (BPMC) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH325832FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, discovers and develops precision therapies for the treatment of cancers and rare diseases. The company offers AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST); and GAVRETO (pralsetinib) against non-small cell lung cancer (NSCLC) in adults. It is investigating fisogatinib for the treatment of advanced hepatocellular carcinoma; BLU-263 targeting indolent systemic mastocytosis. Blueprint Medicines is also advancing pralsetinib inhibitor against RET (Ret Proto-Oncogene) modified medullary thyroid carcinoma and other solid tumors; and avapritinib to treat advanced systemic mastocytosis. The company utilizes its discover engine which combines bioinformatics and drug design capabilities to develop its medicines. Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.

Blueprint Medicines Corp Key Recent Developments

Apr 05,2021: Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New Data Presented at AACR Annual Meeting on Monday, April 12, 2021
Mar 10,2021: Blueprint Medicines to showcase scientific leadership in precision oncology and Hhematology at AACR Annual Meeting 2021
Feb 17,2021: Blueprint medicines reports fourth quarter and full year 2020 financial results

This comprehensive SWOT profile of Blueprint Medicines Corp provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Blueprint Medicines Corp including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Blueprint Medicines Corp – Key Information
Blueprint Medicines Corp – Overview
Blueprint Medicines Corp – Key Employees
Blueprint Medicines Corp – Key Employee Biographies
Blueprint Medicines Corp – Key Operational Heads
Blueprint Medicines Corp – Major Products and Services
Blueprint Medicines Corp – History
Blueprint Medicines Corp – Company Statement
Blueprint Medicines Corp – Locations And Subsidiaries
Blueprint Medicines Corp
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Blueprint Medicines Corp – Business Description
Blueprint Medicines Corp – Corporate Strategy
Blueprint Medicines Corp – SWOT Analysis
SWOT Analysis – Overview
Blueprint Medicines Corp – Strengths
Blueprint Medicines Corp – Weaknesses
Blueprint Medicines Corp – Opportunities
Blueprint Medicines Corp – Threats
Blueprint Medicines Corp – Key Competitors

Section 3 – Company Financial Performance Charts

Blueprint Medicines Corp – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Blueprint Medicines Corp, Key Information
Blueprint Medicines Corp, Key Ratios
Blueprint Medicines Corp, Share Data
Blueprint Medicines Corp, Major Products and Services
Blueprint Medicines Corp, History
Blueprint Medicines Corp, Key Employees
Blueprint Medicines Corp, Key Employee Biographies
Blueprint Medicines Corp, Key Operational Heads
Blueprint Medicines Corp, Other Locations
Blueprint Medicines Corp, Subsidiaries
Blueprint Medicines Corp, Key Competitors
Blueprint Medicines Corp, SWOT Analysis
Blueprint Medicines Corp, Ratios based on current share price
Blueprint Medicines Corp, Annual Ratios
Blueprint Medicines Corp, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Blueprint Medicines Corp (BPMC):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Phoenix Pharmahandel GmbH & Co KG:企業の戦略的SWOT分析
    Phoenix Pharmahandel GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Sypris Solutions Inc (SYPR):企業の財務・戦略的SWOT分析
    Sypris Solutions Inc (SYPR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Syngen Biotech Co Ltd (8279)-製薬・医療分野:企業M&A・提携分析
    Summary Syngen Biotech Co Ltd (Syngen), a part of Standard Chem& Pharm Co Ltd, is a biotechnology company that specializes in strain identification, micro-organism fermentation, recovery, and purification. The company research, develops, manufactures and distributes active pharmaceutical ingredients …
  • Origin Energy Ltd (ORG):企業の財務・戦略的SWOT分析
    Origin Energy Ltd (ORG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Southern California Edison Co:電力:M&Aディール及び事業提携情報
    Summary Southern California Edison Co (SCE), a subsidiary of Edison International, is an electric utility that generates, procures, sources, and supplies electricity. The company generates electricity from various sources including natural gas, hydro, nuclear, solar, and oil and gas. It sources rema …
  • Kunlun Energy Co Ltd (135):石油・ガス:M&Aディール及び事業提携情報
    Summary Kunlun Energy Co Ltd (Kunlun), formerly CNPC (Hong Kong) Ltd, a subsidiary of PetroChina Company Ltd, is an integrated oil and gas company that explores and produces crude oil and natural gas. The company also operates natural gas pipelines, LNG processing and storage facilities and conducts …
  • EnCana Corporation (ECA):石油・ガス:M&Aディール及び事業提携情報
    Summary EnCana Corp (EnCana) is an oil and gas producer. The company explores, develops, produces and markets natural gas, oil and natural gas liquids (NGLs). Its major resource plays include Montney, Duvernay, Wheatland Oil play, Deep Panuke, Horn River and other emerging plays in Canada. In the US …
  • Ur-Energy Inc (URE):企業の財務・戦略的SWOT分析
    Ur-Energy Inc (URE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Yokogawa Electric Corporation:企業の戦略・SWOT・財務分析
    Yokogawa Electric Corporation - Strategy, SWOT and Corporate Finance Report Summary Yokogawa Electric Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Molecular Health GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Molecular Health GmbH (Molecular Health) is a biomedical company that designs, develops, manufactures and commercializes software systems which performs integrated analysis of clinical and genomic patient data to support treatment decisions and provide related services. The company offers Mo …
  • Enerflex Ltd (EFX):企業の財務・戦略的SWOT分析
    Enerflex Ltd (EFX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Women’s Choice Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Women's Choice Pharmaceuticals LLC (WCP) is a pharmaceutical company that offers prescription products for women’s health care and urology markets. The company’s products include fem pH, a therapeutic vaginal jelly that is used to promote and maintain vaginal acidity caused by diabetes, horm …
  • ATUM-製薬・医療分野:企業M&A・提携分析
    Summary ATUM, formerly DNA2.0 Inc is a bioengineering company that provide platforms for protein and vector engineering solutions. The company develops and offers synthetic biology solutions. Its products include expression vectors, electra system, CRISPR/Cas9, proteinpaintbox, cell strains and reag …
  • Sega Sammy Holdings Inc (6460):企業の財務・戦略的SWOT分析
    Sega Sammy Holdings Inc (6460) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Alimentation Couche-Tard Inc. (ATD.B)-石油・ガス分野:企業M&A・提携分析
    Summary Alimentation Couche-Tard Inc. (Couche-Tard) is a retail company that operates an extensive network of convenience stores. The company principally offers food and non-food items as well as transportation fuels. Couche-Tard products include tobacco, alcohol, grocery items, candy, snacks and va …
  • Aldevron LLC-製薬・医療分野:企業M&A・提携分析
    Summary Aldevron LLC (Aldevron) is a custom manufacturing and development service provider. The company manufactures plasmid deoxyribonucleic acid for research, preclinical and clinical applications. It offers nucleic acid, protein, and antibody services. Aldevron's protein production services inclu …
  • BioRestorative Therapies Inc (BRTX):製薬・医療:M&Aディール及び事業提携情報
    Summary BioRestorative Therapies Inc (BRT), formerly Stem Cell Assurance Inc is a developer of therapeutic products and medical therapies. The company performs stem cell programs which include brtxDISC and ThermoStem. brtxDISC,a lead therapeutic product, is designed to offer a non-surgical treatment …
  • Enauta Participacoes SA (QGEP3):企業の財務・戦略的SWOT分析
    Summary Enauta Participacoes SA (Enauta), a subsidiary of Queiroz Galvao Group, is an oil and gas company that explores, develops and produces oil and gas properties. The company's exploration properties include Santos Basin, Espirito Santo Basin, Camamu-Almada Basin, Sergipe-Alagoas Basin, Pernambu …
  • Kazia Therapeutics Ltd (KZA):製薬・医療:M&Aディール及び事業提携情報
    Summary Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology platforms, phosphoinositide 3-kinase (PI3K) inhibitors, anti-tropomyosins (A …
  • Dollarama Inc:戦略・SWOT・企業財務分析
    Dollarama Inc - Strategy, SWOT and Corporate Finance Report Summary Dollarama Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆